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Mutations in genes involved in drug metabolism have been well-associated with drug resis-
tance. Sequence analysis of known antimycobacterial drug-resistant genes is often used to
predict resistance to antibiotics. However, some polymorphisms in such genes may serve a
phylogenetic purpose rather than resistance to drugs. The Beijing family of Mycobacterium
tuberculosis (MTB) is prevalent worldwide and has been associated with the emergence of
multidrug resistance. Sequence type (ST) 10 of the Beijing family is the most predominant
in countries like Peru, Taiwan and Thailand.
A sequence analysis was performed of 81 previously reported drug-resistant associated
genes in multidrug-resistant and pan-susceptible strains of the Beijing family sequence
type 10 of MTB. This analysis revealed 10 synonymous and 12 nonsynonymous single
nucleotide polymorphisms (SNPs) that are shared by all strains under study. One frameshift
mutation was also observed to be common to all. These data might be useful in excluding
some observed SNPs in drug-resistant-associated genes of MTB Beijing ST 10 when per-
forming genotypic drug susceptibility assay.
 2015 Asian African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Introduction
The Beijing family of Mycobacterium tuberculosis (MTB) is of
global importance. It is responsible for 33.2% of prevalent
tuberculosis (TB) cases worldwide [1]. It is largely associated
with multidrug resistance – a more severe form of TB-relapseand outbreaks [2–4]. The genomes of members of the Beijing
family vary widely as they have evolved over the years. Based
on synonymous single nucleotide polymorphisms (SNPs)
from 10 specific chromosomal positions, Filliol et al. divided
MTB Beijing family into 11 sequence types (STs) [5]. ST 19 is
the most predominant in countries such as Japan, while STglang Rd.,
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Peru, Taiwan and Thailand. It is responsible for some of the
outbreaks in these countries [6–9]. A TB outbreak in Thailand
was recently reported to be caused by a multidrug-resistant
(MDR) strain belonging to ST-10 of the Beijing family [10,11].
Next generation sequencing (NGS) has advanced the anal-
ysis of genomes in no small measure. It has been suggested to
have a potential for rapid drug susceptibility testing (DST)
[12]. This is made by predictions from the variants obtained
from the genome sequence analysis of candidate bacterial
isolates. With the availability of NGS, researchers in bioinfor-
matics are focusing on the development of sequence analysis
tools that would be user-friendly for biologists. With the
availability of such programs like CLC genomics work
bench (http://www.clcbio.com/products/clc-main-workbench/
), Lasergene Genomics Suite (http://www.dnastar.com/t-prod-
ucts-dnastar-lasergene-genomics.aspx), and Unipro UGENE
(http://ugene.unipro.ru/), it is relatively easier to analyze the
NGS data in fewer steps from which rapid DST predictions
can be made. Recently, Coll et al. developed an online bioin-
formatics tool, TB Profiler, which can process NGS raw data
to infer strain type and identify known drug-resistance mark-
ers [13]. After the submission of raw sequence data of an iso-
late, all synonymous and nonsynonymous SNPs in drug-
resistant-related genes are displayed. There is, therefore, a
need for the precise understanding of genetic diversity to
ensure accurate predictions of drug susceptibility from geno-
mic data. In this context, it is very important to distinguish
SNPs that are polymorphic in drug-resistant-conferring genes
from the SNPs that play roles in drug resistance.
In order to differentiate SNPs that are polymorphic from
those that confer drug resistance in Beijing ST 10, the whole
genome sequence (WGS) of 17 MDR, 2 pre-extensively drug
resistant (pre-XDR), and 7 pan-susceptible strains were ana-
lyzed; 81 genes that were previously reported to be associated
with resistance to the current and the new anti-TB drugs were
also analyzed. Twenty-two SNPs-10 synonymous and 12
nonsynonymous with 1 frame shift mutation were found to
be shared among all the strains under study and were sug-
gested to be polymorphic rather than drug-resistant–confer-
ring mutations.
Materials and methods
Selection of strains
From the culture collection at the Drug Resistant Tuberculosis
Research Fund Laboratory, Department of Microbiology, Fac-
ulty of Medicine Siriraj Hospital, Mahidol University, Thai-
land, 17 MDR, 2 pre-XDR, and 7 pan-susceptible strains of
the Beijing family sequence type 10 were selected. The pheno-
typic drug susceptibility tests (DSTs) were performed by stan-
dard agar proportion method (Supplementary file 1) [14]. All
strains were identified as SNP cluster group 2, ST 10 of mod-
ern MTB Beijing family [9,15].
Isolation of DNA and whole genome sequencing
Selected strains were subcultured on Loewenstein–Jensen
medium and incubated for 4 weeks at 37 C. DNA extractionwas carried out using cetyltrimethylammonium bromide
(CTAB)-lysozyme method [16]. Isolated genomic DNA samples
were sequenced at Macrogen, Inc., Seoul, South Korea. Geno-
mic libraries were prepared according to the recommenda-
tions of Illumina TrueSeq DNA sample preparation kit. The
library pools were then subjected to paired-end sequencing
on HiSeq 2000 platform (Illumina, San Diego, CA, USA) gener-
ating 100 base pair read length.
Reads mapping and variants calling
Paired-end raw reads of each strain were aligned to the refer-
ence genome MTB H37Rv (GenBank accession number:
AL123456.2) using Bowtie 2 version 2.2.0 [17]. The aligned
reads were sorted, indexed and converted into a mpileup file
using SAMtools [18]. VarScan 2.2.11 was used to determine
the variants [19]. Low-quality bases using the cutoff Phred
quality score of less than or equal to 20 and variants with cov-
erage of less than 10 reads were discarded. Heterozygous sin-
gle nucleotide variants (SNVs) with a minimum allele
frequency of 75% were also discarded, as they are likely to
originate from mapping errors. The remaining variants were
annotated using the H37Rv annotations and classified into
synonymous, nonsynonymous, intergenic or indels. In-house
written Ruby script was used for filtration and annotation
processes. Variants in 81 candidate genes (Supplementary
file 2) were extracted and positions of all determined variants
were then carefully observed in the Integrative Genomics
Viewer (IGV) [20] for further validation.
Ethical approval
Ethical approval was obtained from the Institutional Review
Board Committee of the Faculty of Medicine Siriraj Hospital,
Mahidol University, Thailand (Protocol No. 811/2556; EC2).
Results and discussion
The genetic background of the strains was confirmed by WGS
data analysis. To determine the sequence type according to
Filliol et al. [5], allelic determination at 10 chromosomal posi-
tions were performed. The analysis confirmed that all strains
belong to SNP cluster group (SCG) 2, ST 10 of modern sublin-
eage of the MTB Beijing genotype.
In all 26 strains under study, 81 genes that were previously
reported to be associated with drug resistance were analyzed
for the presence of nucleotide change compared with the ref-
erence genome H37Rv. Mutations corresponding to the drug-
resistant phenotype were observed in all the strains (Supple-
mentary file 3). However, some polymorphisms were observed
in the genes, which were common to MDR, pre-XDR, and pan-
susceptible isolates. These include 10 synonymous SNPs, 12
non-synonymous SNPs and 1 frameshift mutation, Table 1.
In this analysis, all strains have three nonsynonymous
mutations, E21Q, S95T and G668D in gyrA gene and a nonsyn-
onymous mutation R463L in katG gene. Mutations at codon 95
of gyrA and at codon 463 of katG gene are often used to deter-
mine the principle genetic group (PGG) in the MTB complex
[21]. Mutations E21Q and G668D were earlier reported to be
present in both drug-susceptible and drug-resistant isolates,
Table 1 – Common polymorphisms in drug-resistant-related genes present in drug-resistant and pan-susceptible strains.
Drugs Genes Locus Annotations Positions Base change Amino acid change Comments
Quinolones gyrA [32] Rv0006 DNA gyrase subunit A 7362 G > C E21Q Nonsynonymous
7585 G > C S95T Nonsynonymous
9304 G > A G668D Nonsynonymous
Isoniazid Rv1592c [24,25] Rv1592c Conserved hypothetical protein 1,792,777 T > C I322V Nonsynonymous
1,792,778 T > C E321E Synonymous
katG [33] Rv1908c Catalase-peroxidase-peroxy-nitrilase
T katG
2,154,724 C > A R463L Nonsynonymous
accD6 [24,25] Rv2247 Acetyl/propionyl-CoA carboxylase
beta subunit
2,521,342 T > C D200D Synonymous
2,521,428 A > G D229G Nonsynonymous
Ethionamide/Isoniazid mshA [34] Rv0486 Mannosyltransferase 575,907 C > T A187V Nonsynonymous
nudC [35] Rv3199c NADH pyrophosphatase 3,571,828 G > C P239R Nonsynonymous
Streptomycin tap [36] Rv1258c Conserved membrane
transport protein
1,406,760 AG > ACG InsC580–581 Frame shift
gidB [26,37] Rv3919c Probable glucose-inhibited
division protein B
4,407,588 T > C A205A Synonymous
4,407,927 T > G E92D Nonsynonymous
Rifampicin rpoB [38] Rv0667 DNA-directed RNA polymerase beta chain 763,031 T > C A1075A Synonymous
Ethambutol embC [39] Rv3793 Membrane indolylacetylinositol
arabinosyltransferase embC
4,242,643 C > T R927R Synonymous
embA [39] Rv3794 Membrane indolylacetylinositol
arabinosyltransferase embA
4,243,460 C > T C76C Synonymous
Thiacetazone mmaA2 [29] Rv0644c Methoxy mycolic acid synthase 2 738,522 T > G E213D Nonsynonymous
Pyrazinamide rpsA [40] Rv1630 30S ribosomal protein S1 1,834,177 A > C R212R Synonymous
Capreomycin tlyA [41] Rv1694 Cytotoxin/haemolysin homologue 1,917,972 A > G L11L Synonymous
Cycloserine cycA [42] Rv1704c D-serine/alanine/glycine transporter protein 1,931,179 C > A R93L Nonsynonymous
Cycloserine ddlA [43,44] Rv2981c D-alanine-D-alanine ligase 3,336,825 T > C T365A Nonsynonymous
PA-824 fgd1 [45,46] Rv0407 F420-dependent glucose-6-phosphate dehydrogenase 491,742 T > C F320F Synonymous
Benzothiazinones (BTZ043) dprE1 [47–50] Rv3790 Probable oxidoreductase 4,236,237 C > T T153T Synonymous
Note: Positions are referred to the positions of H37Rv reference.
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genes – Rv1592c and accD6 were found to be transcriptionally
induced by isoniazid, suggesting the genes as new drug targets
[24]. A previous study identified 2 nonsynonymous mutations
– P42L and V430A in Rv1592c present in isoniazid-resistant iso-
lates, but absent in isoniazid-susceptible isolates [25].
Although none of these mutations were found in studied
strains, a synonymous E321E and a nonsynonymous I322V
were observed in Rv1592c. Genetic variations in the gidB gene
in conferring streptomycin resistance in MTB have been well
described [26]. A common synonymous A205A and a nonsyn-
onymous E92D substitution in the gidB gene were found. The
E92D mutation was earlier reported in both drug-susceptible
and -resistant strains and was described as being a specific
SNP for the Beijing family [27]. A common frame shift muta-
tion as a result of a nucleotide insertion (InsC580–581) in tap
gene (Rv1258c) was found in this study. The insertion had been
reported to be exclusive to the Beijing family, and a simple
PCR-RFLP technique was developed for rapid identification of
the MTB Beijing family [28]. Although the studied strains were
not confirmed for thiacetazone and cycloserine susceptibility,
some common mutations were found in the genes related to
their resistance and are likely not to have a potential role in
drug resistance. The mmaA2 gene was suspected to have a role
in thiacetazone resistance [29]. A common nonsynonymous
mutation E213D in mmaA2 genes of the studied strains was
found. Previous studies using WGS analysis of MTB Beijing iso-
lates reported this mutation to be present in all susceptible
and resistant isolates [12,22,30,31]. This mutation appears to
be a genetic marker for the Beijing genotype rather than play-
ing a role in drug resistance. Mutations R39L were found in
cycA and T365A in ddlA genes that are involved in cycloserine
resistance. The MTB phylogeographic diversity project
reported both SNPs in Mycobacterium canettii and all six lin-
eages of MTB except in MTB H37Rv [31]. These substitutions
are considered as ancestral and are not significant for cyclo-
serine resistance [12]. Among the studied strains, no nonsyn-
onymous SNPs were found in atpE, fgd1, dprE1 reportedly
involved in resistance to Bedaquiline, PA-824 and BTZ043,
respectively. However, common synonymous mutations
F320F in fgd1 gene and T153T in dprE1 gene were observed.
The results of an in-depth genomic analysis of a compre-
hensive list of antimycobacterial drug-resistant-associated
genes in MDR, pre-XDR and pan-susceptible strains of ST 10
Beijing family of MTB are presented in this study. The collec-
tion of the observed common variants will clear the doubts
regarding their involvement in drug resistance. These data
might be useful in excluding some observed SNPs in drug-
associated genes of MTB Beijing ST 10 during genotypic drug
susceptibility assay.
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